Catalyst Enrolls First MuSK MG Patient in Phase 3 Trial Evaluating Firdapse
Catalyst Pharmaceuticals recently enrolled the first patient into a Phase 3 clinical trial designed to evaluate the efficacy and…
Articles by Margarida Azevedo, MSc
Dosing Completed in Phase 1 Study of GTP-004 for Myasthenia Gravis Treatment Side Effects
Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated…
Soliris Approved to Treat Myasthenia Gravis Patients Who Are AChR Antibody-positive in Japan
Alexion Pharmaceuticals announced that it has received approval to market Soliris (eculizumab) in Japan as a treatment for certain adults with…
Myasthenia Gravis Foundation’s Upcoming MG Walks Raise Funds and Awareness
The Myasthenia Gravis Foundation of America (MGFA) started the MG Walk Campaign six years ago to raise funds, create awareness,…
Assistance Fund Opens Co-Pay Program for Myasthenia Gravis Patients
The Assistance Fund recently launched a program to provide financial support to patients with myasthenia gravis (MG). The Assistance…
Alexion Receives Extended Patent in Japan for Soliris (Eculizumab)
The Japanese Patent Office (JPO) has issued a new patent for the composition of eculizumab, marketed as Soliris by…
argenx Doses First Subject in Study Evaluating Subcutaneous ARGX-113 for Autoimmune Diseases
The first participant has been dosed in a Phase 1 clinical trial evaluating argenx‘s subcutaneous formulation of ARGX-113 in healthy…
FDA Approves Soliris for Particular Type of Myasthenia Gravis
The U.S. Food and Drug Administration has approved Soliris (eculizumab) as a treatment for adults with a particular type of …
FDA Grants Orphan Drug Status to Argenx’s ARGX-113 for Treating Myasthenia Gravis
The U.S. Food and Drug Administration has granted orphan drug status to ARGX-113, a potential treatment for myasthenia gravis, its…
Women with Myasthenia Gravis Report Lower Quality of Life than Male MG Patients, Study Finds
Women with myasthenia gravis (MG) have a poorer quality of life than male patients. That’s the conclusion of a…